Roche has entered an agreement with Israeli provider of artificial intelligence (AI)-based cancer diagnostics Ibex Medical Analytics, a global leader in artificial intelligence (AI)-based cancer diagnostics, the company announced Monday.
Follow Israel Hayom on Facebook and Twitter
The companies will jointly develop an embedded image analysis workflow for pathologists to seamlessly access Ibex's AI algorithms, insights, and decision support tools using NAVIFY Digital Pathology, the cloud version of Roche's uPath enterprise software. Collaborations with leading AI companies like Ibex are made possible through Roche's Digital Pathology Open Environment, which allows pathologists to securely access third-party AI-powered technology alongside Roche's growing menu of AI-based image analysis tools.
Customers using Roche Digital Pathology will gain access to Ibex's innovative tools, such as algorithms that analyze prostate and breast biopsies, in addition to the AI tools already provided by Roche.
Ibex's Gale platform was recently granted Breakthrough Device Designation by the US Food and Drug Administration (FDA) and is CE marked in Europe for breast and prostate cancer detection in multiple workflows.
"With the addition of Ibex's clinical-grade image analysis tools to our NAVIFY Digital Pathology menu, we can aid pathologists and providers in delivering value-based patient care by increasing their efficiency and accuracy for higher quality cancer diagnosis," said Jill German, Head of Roche Diagnostics Pathology Customer Area.
"Digital pathology provides the capability to introduce new, innovative ways for laboratories to improve quality and efficiency of cancer diagnosis. Together with Roche, we look forward to transforming pathology by delivering powerful AI-based tools to the fingertips of pathologists," said Joseph Mossel, co-founder and CEO of Ibex Medical Analytics.
